Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Urbonas, V.
  • Schadendorf, D.
  • Zimmer, L.
  • Danson, S. ORCID logo https://orcid.org/0000-0002-3593-2890
  • Marshall, E.
  • Corrie, P.
  • Wheater, M.
  • Plummer, E.
  • Mauch, C.
  • Scudder, C.
  • Goff, M.
  • Love, S.B.
  • Mohammed, S.B.
  • Middleton, M.R.
Copyright, Publisher and Additional Information:

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Phase II; melanoma; BRAF wild-type; pazopanib; trametinib
Dates:
  • Published: February 2019
  • Published (online): 14 November 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 01 Feb 2019 12:55
Last Modified: 02 Nov 2021 15:16
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: 10.1093/annonc/mdy500
Related URLs:
Open Archives Initiative ID (OAI ID):

Download

Export

Statistics